NEW YORK (Reuters Health)—Tabalumab, a monoclonal antibody to B-cell activating factor, was modestly better than placebo in relieving symptoms of systemic lupus erythematosus (SLE), according to results from the ILLUMINATE-2 trial. “Lupus is a complicated disease that does not behave the same way in all patients who share the clinical symptoms,” Dr. Joan T. Merrill…
How Hospitals Rank in Treating Childhood-Onset SLE
A recent study of how medical facilities in three countries meet minimum care standards for patients with childhood-onset systemic lupus erythematosus found a wide variation in quality of care…
Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report
A 35-year-old female with a history of systemic lupus erythematosus (SLE) without kidney involvement was admitted to our hospital with low-grade fevers, headache, increasing lower extremity edema and elevated blood pressure. History She was first diagnosed with SLE as a teenager when she developed oral ulcers and pleuritic chest pain and tested positive for anti-Smith…
Understanding SLE-Associated Skin Injury May Open the Door to Therapies
In a recent review, researchers addressed skin injury in patients with SLE, discussing the effects of ultraviolet rays on the skin and the subsequent generation of autoantibodies. They concluded that UV rays activate immune cells where IgG has been deposited, resulting in inflammation…
The ACR’s Lupus Initiative Expands Training, Educational Resources
The Lupus Initiative (TLI) has been an emergent creation inside the American College of Rheumatology (ACR) for the past six years. In 2009, the Office of Minority Health and Office of Women’s Health (now called the Office of Health Disparities) solicited an application from the ACR to develop resources for educating non-rheumatologists, both in training…
Infection & Hospitalization in SLE
From 1996–2011, the rates of hospitalization due to serious infectious diseases in patients with systemic lupus erythematosus (SLE) increased substantially, according to new research. In a retrospective data-driven study, researchers plotted and compared hospitalization and in-hospital mortality rates of SLE and non-SLE populations, determining the trends for the five most common infections…
New Study Examines Pregnancy Risk Factors for Patients with Lupus
Important new findings show that a majority of women with inactive or stable SLE can have successful pregnancies without experiencing flares and give birth to infants who survive the neonatal period…
The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis
CHICAGO—With the approval of the Jak inhibitors (i.e., jakinibs) tofacitinib and ruxolitinib—and others being investigated—rheumatologists need to arm themselves with an understanding of these drugs so they can think critically when evaluating them and deciding how to use them, said John O’Shea, MD, chief of the Molecular Immunology and Inflammation Branch of and scientific director…
Rontalizumab May Help Patients with Lupus & Low Interferon Signature
In a Phase 2 study, researchers found that rontalizumab was a more effective treatment in patients with systemic lupus erythematosus who had an interferon signature metric score lower than 1.
Study Reveals Role of IL-17–Secreting CD4+ T Cells in Lupus
Patients with systemic lupus erythematosus (SLE) are characterized by high-titer, highly specific, isotype-switched antibodies against DNA and RNA. Patients have both CD4+ T helper (Th) cell- dependent as well as Th cell-independent autoantibody production. Two mouse models of lupus demonstrate T-cell–independent autoantibody production: the pristane model of lupus, as well as in the MRL/lpr mouse…
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 45
- Next Page »